Fibrinogen turnover during the treatment with xantinol nicotinate.
D000284:Administration, Oral; D001161:Arteriosclerosis / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects; D003692:Delayed-Action Preparations; D005340:Fibrinogen / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007456:Iodine Isotopes; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D011233:Precipitin Tests; D013806:Theophylline / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D003692:Delayed-Action Preparations; D005343:Fibrinolytic Agents; D007456:Iodine Isotopes; D009539:Nicotinic Acids; D005340:Fibrinogen; D013806:Theophylline